Inflammation and treatment response to sertraline in patients with coronary heart disease and comorbid major depression

Journal of Psychosomatic Research

Volumn 71, Issue 1, 2011, Pages 13-17

  Bot, Mariska ^a   Carney, Robert M ^b   Freedland, Kenneth E ^b   Rubin, Eugene H ^b   Rich, Michael W ^b   Steinmeyer, Brian C ^b   Mann, Douglas L ^b  

^a TILBURG UNIVERSITY   (Netherlands)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Coronary heart disease; Depression; Inflammation; Treatment response

Indexed keywords

C REACTIVE PROTEIN; CORN OIL; CREATININE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID ESTER; PLACEBO; SERTRALINE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BECK DEPRESSION INVENTORY; BLOOD ANALYSIS; CARDIAC PATIENT; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; COMORBIDITY; CONTROLLED STUDY; CORRELATIONAL STUDY; CREATININE BLOOD LEVEL; DIZZINESS; DRUG WITHDRAWAL; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFLAMMATION; INSOMNIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL PATIENT; MOUTH TEMPERATURE; PATIENT COMPLIANCE; PREDICTION; PROTEIN BLOOD LEVEL; SECONDARY ANALYSIS; TREATMENT DURATION; TREATMENT REFUSAL; TREATMENT RESPONSE; TREATMENT WITHDRAWAL;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY DISEASE; DEPRESSIVE DISORDER, MAJOR; DRUG THERAPY, COMBINATION; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-6; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SERTRALINE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79958770669     PISSN: 00223999     EISSN: 18791360     Source Type: Journal    
DOI: 10.1016/j.jpsychores.2010.11.006     Document Type: Article

References (28)

1. van Melle JP, de Jonge P, Spijkerman TA, Tijssen JG, Ormel J, van Veldhuisen DJ, et al. Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis. Psychosom Med 2004, 66:814-822.
2. Barth J, Schumacher M, Herrmann-Lingen C Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis. Psychosom Med 2004, 66:802-813.
3. de Jonge P, van den Brink RH, Spijkerman TA, Ormel J Only incident depressive episodes after myocardial infarction are associated with new cardiovascular events. J Am Coll Cardiol 2006, 48:2204-2208.
4. Carney RM, Freedland KE, Steinmeyer B, Blumenthal JA, de Jonge P, Davidson KW, et al. History of depression and survival after acute myocardial infarction. Psychosom Med 2009, 71:253-259.
5. Carney RM, Freedland KE Treatment-resistant depression and mortality after acute coronary syndrome. Am J Psychiatry 2009, 166:410-417.
6. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107:499-511.
7. Howren MB, Lamkin DM, Suls J Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 2009, 71:171-186.
8. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-analysis of cytokines in major depression. Biological Psychiatry 2010, 67:446-457.
9. Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 2000, 22:370-379.
10. Eller T, Vasar V, Shlik J, Maron E Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:445-450.
11. Basterzi AD, Aydemir C, Kisa C, Aksaray S, Tuzer V, Yazici K, et al. IL-6 levels decrease with SSRI treatment in patients with major depression. Hum Psychopharmacol 2005, 20:473-476.
12. Shimbo D, Rieckmann N, Paulino R, Davidson KW Relation between C reactive protein and depression remission status in patients presenting with acute coronary syndrome. Heart 2006, 92:1316-1318.
13. Carney RM, Freedland KE, Rubin EH, Rich MW, Steinmeyer BC, Harris WS Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease: a randomized controlled trial. JAMA 2009, 302:1651-1657.
14. Beck AT, Steer RA, Brown GK BDI-II: Beck Depression Inventory manual 1996, Psychological Corp, San Antonio (TX). 2nd ed.
15. Hedlund JL, Viewig BW The Hamilton rating scale for depression: a comprehensive review. Journal of Operational Psychiatry 1979, 10:149-165.
16. Janssen DG, Caniato RN, Verster JC, Baune BT A psychoneuroimmunological review on cytokines involved in antidepressant treatment response. Hum Psychopharmacol 2010, 25:201-215.
17. Schins A, Tulner D, Lousberg R, Kenis G, Delanghe J, Crijns HJ, et al. Inflammatory markers in depressed post-myocardial infarction patients. J Psychiatr Res 2005, 39:137-144.
18. Prasad K C-reactive protein (CRP)-lowering agents. Cardiovasc Drug Rev 2006, 24:33-50.
19. Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 2003, 108:2317-2322.
20. Ridker PM, Hennekens CH, Buring JE, Rifai N C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342:836-843.
21. Calder PC n-3 Polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 2006, 83:1505S-1519S.
22. Schweizer E, Rynn M, Mandos LA, Demartinis N, Garcia-Espana F, Rickels K The antidepressant effect of sertraline is not enhanced by dose titration: results from an outpatient clinical trial. Int Clin Psychopharmacol 2001, 16:137-143.
23. Fabre LF, Abuzzahab FS, Amin M, Claghorn JL, Mendels J, Petrie WM, et al. Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo. Biol Psychiatry 1995, 38:592-602.
24. Ridker PM Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003, 107:363-369.
25. Scott J Predictors of non-response to antidepressants. Refractory depression: current strategies and future directions. 1995, 19-28. John Wiley, Chichester. W.A. Nolen, J. Zohar, S.P. Roose, J.D. Amsterdam (Eds.).
26. Souery D, Lipp O, Massat I, Mendlewicz J The characterization and definition of treatment-resistant mood disorders. Treatment-resistant mood disorders 2001, 3-29. Cambridge University Press, Cambridge. J.D. Amsterdam, M. Hornig, A.A. Nierenberg (Eds.).
27. Rush AJ, Wisniewski SR, Warden D, Luther JF, Davis LL, Fava M, et al. Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. Arch Gen Psychiatry 2008, 65:870-880.
28. Fagiolini A, Kupfer DJ Is treatment-resistant depression a unique subtype of depression?. Biol Psychiatry 2003, 53:640-648.